Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

NCT03075423 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

316

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: Ipilimumab plus nivolumab
DRUG: Standard Therapy

Sponsor

Goethe University